*Based on commercial patients, early access patients, and clinical trial participants through December 2019.
Safety and efficacy
evaluated
in the longest
clinical trial in
SMA to date
SPINRAZA is delivered directly to
the central nervous system (CNS)
where
motor neuron loss begins.
After
initial loading doses,
SPINRAZA is
given 3 times a year.
There’s someone from almost every age group who has been treated with SPINRAZA.
†Includes clinical trial patients.
‡Clinical studies of SPINRAZA did not include sufficient numbers of subjects aged 65 and older to determine
whether they respond differently from younger patients.
§Based on commercial patients in the US (including Puerto
Rico) through December 2019.
The most common side effects of SPINRAZA include lower respiratory infection, fever, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome. These are not all of the possible side effects of SPINRAZA.